Table 2.
Resistant trends of Shigella strains to different antibiotics
| Drugs | 2001 (n = 19) | 2002 (n = 49) | 2003 (n = 144) | 2004 (n = 60) | 2005 (n = 80) | 2006 (n = 55) | 2007 (n = 56) | 2008 (n = 63) | Total (n = 526) | P |
|---|---|---|---|---|---|---|---|---|---|---|
| CFZ | 0 | 0 | 3 (2·1) | 0 | 4 (5) | 3 (5·5) | 17 (30·4) | 10 (15·9) | 37 (7·0) | 0·000* |
| CTX | 0 | 0 | 3 (2·1) | 0 | 2 (2·5) | 3 (5·5) | 5 (8·9) | 5 (7·9) | 18 (3·4) | 0·024* |
| AMC | 18 (94·7) | 45 (91·8) | 133 (92·4) | 51 (85) | 76 (95) | 41 (74·5) | 48 (85·7) | 57 (90·5) | 469 (89·2) | 0·017† |
| AMP | 18 (94·7) | 46 (93·9) | 133 (92·4) | 51 (85) | 80 (100) | 41 (74·5) | 51 (91·1) | 62 (98·4) | 482 (91·6) | 0·000† |
| GM | 0 | 2 (4·1) | 3 (2·1) | 0 | 8 (10) | 1 (1·8) | 6 (10·7) | 4 (6·3) | 24 (4·6) | n.s. |
| TOB | 1 (5·3) | 2 (4·1) | 3 (2·1) | 4 (6·7) | 12 (15) | 2 (3·6) | 3 (5·4) | 11 (17·5) | 38 (7·2) | n.s. |
| C | 19 (100) | 48 (98) | 134 (93·1) | 51 (85) | 80 (100) | 55 (100) | 48 (85·7) | 57 (90·5) | 492 (93·5) | 0·000† |
| TE | 19 (100) | 48 (98) | 144 (100) | 59 (98·3) | 79 (98·8) | 55 (100) | 54 (96·4) | 63 (100) | 521 (99·0) | n.s. |
| SMZ | 19 (100) | 40 (81·6) | 130 (90·3) | 47 (78·3) | 65 (81·3) | 45 (81·8) | 34 (60·7) | 42 (66·7) | 422 (80·2) | 0·000† |
| PB | 0 | 0 | 1 (0·7) | 0 | 0 | 0 | 0 | 0 | 1 (0·2) | n.s. |
| NAL | 18 (95) | 49 (100) | 144 (100) | 60 (100) | 80 (100) | 55 (100) | 56 (100) | 63 (100) | 525 (99·8) | n.s. |
| PI | 18 (95) | 49 (100) | 144 (100) | 60 (100) | 80 (100) | 55 (100) | 56 (100) | 63 (100) | 525 (99·8) | n.s. |
| CIP | 0 | 2 (4·1) | 16 (11·1) | 19 (31·7) | 28 (35) | 16 (29·1) | 22 (39·3) | 36 (57·1) | 139 (26·4) | 0·000* |
| F | 0 | 0 | 0 | 0 | 1 (1·3) | 0 | 0 | 0 | 1 (0·2) | n.s. |
AMP, Ampicillin; AMC, amoxicillin; C, chloramphenicol; CFZ, cefamezin; CIP, ciprofloxacin; CTX, cefotaxime; F, furazolidone; GM, gentamicin; NAL, nalidixic acid; PB, polymyxin B; PI, pipemidic acid; SMZ, co-trimoxazole; TE, tetracycline; TOB, tobramycin.
n, Total number of strains; n.s., not significant.
Numbers within parentheses indicate percentage.
*
Statistically significant increase mean rank in resistance to the antibiotic in question during the years of comparison.
†
Significantly decreasing.